Knockdown of HE4 suppresses aggressive cell growth and malignant progression of ovarian cancer by inhibiting the JAK/STAT3 pathway
Open Access
- 2 September 2019
- journal article
- research article
- Published by The Company of Biologists in Biology Open
- Vol. 8 (9) , bio043570
Abstract
Human epididymis protein 4 (HE4) is well known to be a predictor of ovarian cancer clinically. HE4 is reported to play crucial roles in ovarian cancer progression and metastasis. The purpose of the present study was to explore its biological role and molecular mechanism in ovarian cancer. In our study, we found that expression levels of HE4 in tissues, serum and urine in ovarian cancer were upregulated compared to healthy and benign groups. HE4 expression was elevated in ovarian cancer cells. Knockdown of HE4 dampened cell proliferation and Ki67 expression, as well as enhanced apoptosis, caspase-3 activity and cleaved-caspase-3 expression. In addition, HE4 downregulation repressed invasion and migration capabilities of ovarian cancer cells. Western blot analyses showed that knockdown of HE4 reduced the levels of matrix metalloproteinases (MMP-2 and MMP-9) and inhibited epithelial to mesenchymal transition (EMT) in ovarian cancer cells. In vivo animal experiments revealed that HE4 downregulation constrained the growth of xenograft tumor. Mechanism research showed that knockdown HE4 inhibited the activity of JAK/STAT3 pathway in vitro and in vivo. In conclusion, our findings reported that knockdown of HE4 suppresses aggressive cell growth and malignant progression of ovarian cancer by inhibiting the JAK/STAT3 pathway, which provides valuable insights to contribute to develop novel HE4-targeted therapies.Keywords
This publication has 27 references indexed in Scilit:
- HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell LinesInternational Journal of Molecular Sciences, 2013
- Regulatory networks defining EMT during cancer initiation and progressionNature Reviews Cancer, 2013
- Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment responseDiagnostic Pathology, 2013
- Serum HE4 as a diagnostic and prognostic marker for lung cancerTumor Biology, 2012
- Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathwayToxicology and Applied Pharmacology, 2012
- Rethinking ovarian cancer: recommendations for improving outcomesNature Reviews Cancer, 2011
- HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseasesTumor Biology, 2011
- Serum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian CancerAnnals of Surgical Oncology, 2011
- Epithelial–mesenchymal transition in ovarian cancerCancer Letters, 2010
- A reciprocal repression between ZEB1 and members of the miR‐200 family promotes EMT and invasion in cancer cellsEMBO Reports, 2008